Avalo CEO granted 286,000 stock options

NEIL GARRY ARTHUR reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

NEIL GARRY ARTHUR reported acquisition or exercise transactions in this Form 4 filing.

Avalo Therapeutics, Inc. reported that Chief Executive Officer Neil Garry Arthur received a grant of stock options covering 286,000 shares on February 26, 2026. The option vests 25% on February 26, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, subject to his continued service.

Insider Trade Summary

Grant/Award: 286,000 shares

Grant/Award 1 txn

Insider NEIL GARRY ARTHUR

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	286,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 286,000 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests twenty-five percent (25%) on February 26, 2027 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Avalo Therapeutics (AVTX) report for Neil Garry Arthur?

Avalo Therapeutics reported a stock option grant to CEO Neil Garry Arthur for 286,000 shares. The award is a derivative security, classified as a grant or award acquisition, and reflects direct ownership following the transaction according to the Form 4 details.

How many Avalo Therapeutics (AVTX) options were granted to the CEO?

The CEO of Avalo Therapeutics received a grant of stock options covering 286,000 shares. These options are reported as derivative securities, with 286,000 options shown as beneficially owned following the transaction, according to the Form 4 insider filing for February 26, 2026.

What is the vesting schedule for the Avalo Therapeutics (AVTX) CEO’s new options?

The stock option vests 25% on February 26, 2027, with the remaining 75% vesting in equal monthly installments over the next three years. Vesting is conditioned on Neil Garry Arthur’s continued service with Avalo Therapeutics on each applicable vesting date, as disclosed in the filing footnote.

Is the Avalo Therapeutics (AVTX) CEO’s option grant a buy or a sale of shares?

The transaction is an acquisition of derivative securities through a grant, not an open-market buy or sale. It is classified with transaction code “A” for grant, award, or other acquisition, reflecting compensation rather than a discretionary stock market trade by the CEO.

Does the Avalo Therapeutics (AVTX) Form 4 show direct or indirect ownership for the new options?

The Form 4 shows the 286,000 stock options as held under direct ownership. The direct_or_indirect field is marked “D,” and no footnote indicates that a separate entity, trust, or family vehicle holds voting or investment power over these derivative securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 04:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NEIL GARRY ARTHUR

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$17.64	02/26/2026		A		286,000		(1)	02/26/2036	Common Stock	286,000	$0	286,000	D

Explanation of Responses:

1. The stock option vests twenty-five percent (25%) on February 26, 2027 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.

	/s/ Christopher Sullivan, Attorney-in-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.